Fmoc-L-arginine(Alloc)2-al | 1245141-39-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: Fmoc-L-arginine(Alloc)2-al
• 英文别名: Fmoc-Arg(Alloc)2-H
• CAS: 1245141-39-2
• 化学式: C₂₉H₃₂N₄O₇
• 分子量: 548.596
• InChiKey: QFJNRWRKBXGNNN-FQEVSTJZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.05
• 重原子数：
  40.0
• 可旋转键数：
  12.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  144.42
• 氢给体数：
  3.0
• 氢受体数：
  7.0

反应信息

• 作为反应物：
  描述：

  庚二酸 、 Fmoc-L-arginine(Alloc)2-al 、 Fmoc-甘氨酸 、 BOC-L-苯丙氨酸 在 1-羟基苯并三唑 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 N,N-二异丙基乙胺 、 哌啶 作用下， 以 N-甲基吡咯烷酮 为溶剂， 以0.8 mg的产率得到2-((2S,6S)-2-benzyl-6-(3-guanidinopropyl)-3,8,14-trioxo-1,4,7-triazacyclotetradecan-4-yl)acetamide
  参考文献：
  名称：

  Rational conversion of noncontinuous active region in proteins into a small orally bioavailable macrocyclic drug-like molecule: The HIV-1 CD4:gp120 paradigm

  摘要：

  Rational conversion of noncontinuous active regions of proteins into a small orally bioavailable molecule is crucial for the discovery of new drugs based on inhibition of protein-protein interactions. We developed a method that utilizes backbone cyclization as an intermediate step for conversion of the CD4 noncontinuous active region into small macrocyclic molecules. We demonstrate that this method is feasible by preparing small inhibitor for human immunodeficiency virus infection. The lead compound, CG-1, proved orally available in the rat model. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2010.04.053
• 作为产物：
  描述：

  Fmoc-L-arginine(Alloc)2-ol 在 戴斯-马丁氧化剂 作用下， 以 二氯甲烷 为溶剂， 反应 2.67h， 生成 Fmoc-L-arginine(Alloc)2-al
  参考文献：
  名称：

  Rational conversion of noncontinuous active region in proteins into a small orally bioavailable macrocyclic drug-like molecule: The HIV-1 CD4:gp120 paradigm

  摘要：

  Rational conversion of noncontinuous active regions of proteins into a small orally bioavailable molecule is crucial for the discovery of new drugs based on inhibition of protein-protein interactions. We developed a method that utilizes backbone cyclization as an intermediate step for conversion of the CD4 noncontinuous active region into small macrocyclic molecules. We demonstrate that this method is feasible by preparing small inhibitor for human immunodeficiency virus infection. The lead compound, CG-1, proved orally available in the rat model. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2010.04.053